{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:59:26Z","timestamp":1791518366571,"version":"4.3.4"},"reference-count":100,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:p>Of the nearly 600,000 people in the U.S. who receive dialysis for chronic kidney failure, &amp;gt;60% have diabetes. People receiving dialysis who have diabetes have worse overall and cardiovascular survival rates than those without diabetes. Diabetes care in the dialysis setting is complicated by kidney failure\u2013related factors that render extrapolation of glycated hemoglobin (HbA1c) targets to the dialysis population unreliable and may change the risk-benefit profiles of glucose-lowering and disease-modifying therapies. No prospective studies have established the optimal glycemic targets in the dialysis population, and few randomized clinical trials of glucose-lowering medications included individuals receiving dialysis. Observational data suggest that both lower and higher HbA1c are associated with mortality in the dialysis population. Existing data suggest the potential for safety and effectiveness of some glucose-lowering medications in the dialysis population, but firm conclusions are hindered by limitations in study design and sample size. While population-specific knowledge gaps about optimal glycemic targets and diabetes medication safety and effectiveness preclude the extension of all general population diabetes guidelines to the dialysis-dependent diabetes population, these uncertainties should not detract from the importance of providing person-centered diabetes care to people receiving dialysis. Diabetes care for individuals with and without dialysis-dependent kidney failure should be holistic, based on individual preferences and prognoses, and tailored to integrate established treatment approaches with proven benefits for glycemic control and cardiovascular risk reduction. Additional research is needed to inform how recent pharmacologic and technological advances can be applied to support such individualized care for people receiving maintenance dialysis.<\/jats:p>","DOI":"10.2337\/dci24-0081","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:03:33Z","timestamp":1734527013000},"page":"164-176","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":19,"title":["Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure"],"prefix":"10.2337","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-9054","authenticated-orcid":false,"given":"Klara R.","family":"Klein","sequence":"first","affiliation":[{"name":"1Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":false,"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[{"name":"2Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX"},{"name":"3Peter O\u2019Donnel Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"4Division of Nephrology, University of Washington School of Medicine, Seattle, WA"},{"name":"5Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Flythe","sequence":"additional","affiliation":[{"name":"6Division of Nephrology and Hypertension, University of North Carolina School of Medicine, Chapel Hill, NC"},{"name":"7Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"2025012220114999300_B1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.15585\/mmwr.mm7111a3","article-title":"Reported cases of end-stage kidney disease\u2013United States, 2000-2019","volume":"71","author":"Burrows","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025012220114999300_B2","author":"United States Renal Data System","year":"2021"},{"key":"2025012220114999300_B3","doi-asserted-by":"crossref","first-page":"e14775","DOI":"10.1111\/dme.14775","article-title":"Excess all-cause and cause-specific mortality for people with diabetes and end-stage kidney disease","volume":"39","author":"Morton","year":"2022","journal-title":"Diabet Med"},{"key":"2025012220114999300_B4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamacardio.2021.4234","article-title":"Analysis of respiratory fluoroquinolones and the risk of sudden cardiac death among patients receiving hemodialysis","volume":"7","author":"Assimon","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025012220114999300_B5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ahj.2020.10.055","article-title":"Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease","volume":"231","author":"Shavadia","year":"2021","journal-title":"Am Heart J"},{"key":"2025012220114999300_B6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41574-020-00425-6","article-title":"The trials and tribulations of determining HbA1c targets for diabetes mellitus","volume":"16","author":"Klein","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2025012220114999300_B7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2025012220114999300_B8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1681\/ASN.2006070772","article-title":"Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection","volume":"18","author":"Inaba","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025012220114999300_B9","author":"United States Renal Data System","year":"2023"},{"key":"2025012220114999300_B10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2337\/dc06-2127","article-title":"A1C and survival in maintenance hemodialysis patients","volume":"30","author":"Kalantar-Zadeh","year":"2007","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B11","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2215\/CJN.08921010","article-title":"Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus","volume":"6","author":"Duong","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025012220114999300_B12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/db11-1015","article-title":"Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study","volume":"61","author":"Ricks","year":"2012","journal-title":"Diabetes"},{"key":"2025012220114999300_B13","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2337\/dc17-0110","article-title":"Association of glycemic status during progression of chronic kidney disease with early dialysis mortality in patients with diabetes","volume":"40","author":"Rhee","year":"2017","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B14","doi-asserted-by":"crossref","first-page":"e005581","DOI":"10.1161\/JAHA.117.005581","article-title":"Associations of glycemic control with cardiovascular outcomes among US hemodialysis patients with diabetes mellitus","volume":"6","author":"Rhee","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025012220114999300_B15","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/CIRCULATIONAHA.109.857268","article-title":"Glycemic control and cardiovascular events in diabetic hemodialysis patients","volume":"120","author":"Drechsler","year":"2009","journal-title":"Circulation"},{"key":"2025012220114999300_B16","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2337\/dc12-0573","article-title":"Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"35","author":"Ramirez","year":"2012","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B17","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2215\/CJN.09301209","article-title":"Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses","volume":"5","author":"Williams","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025012220114999300_B18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.kint.2017.02.008","article-title":"Unique hemoglobin A1c level distribution and its relationship with mortality in diabetic hemodialysis patients","volume":"92","author":"Hoshino","year":"2017","journal-title":"Kidney Int"},{"key":"2025012220114999300_B19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2013.06.020","article-title":"Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis","volume":"63","author":"Hill","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B20","doi-asserted-by":"crossref","first-page":"i219","DOI":"10.1093\/ndt\/gfw169.10","article-title":"Unique hemoglobin A1c level distribution and its relationship with mortality seen for diabetic Japanese hemodialysis patients: results from the Japanese dialysis outcomes and practice patterns study","volume":"31","author":"Hoshino","year":"2016","journal-title":"Nephrol Dialysis Transplant"},{"key":"2025012220114999300_B21","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc24-S006","article-title":"6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"key":"2025012220114999300_B24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2025012220114999300_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2021.09.010","article-title":"KDOQI US commentary on the KDIGO 2020 clinical practice guideline for diabetes management in CKD","volume":"79","author":"Mottl","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.ajkd.2023.09.003","article-title":"KDOQI commentary on the KDIGO 2022 update to the clinical practice guideline for diabetes management in CKD","volume":"83","author":"Mottl","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B27","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B28","first-page":"S117","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025012220114999300_B29","doi-asserted-by":"crossref","first-page":"e15027","DOI":"10.1111\/dme.15027","article-title":"Management of adults with diabetes on dialysis: summary of recommendations of the Joint British Diabetes Societies guidelines 2022","volume":"40","author":"Frankel","year":"2023","journal-title":"Diabet Med"},{"key":"2025012220114999300_B30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2215\/CJN.04510422","article-title":"Continuous glucose monitoring to optimize management of diabetes in patients with advanced CKD","volume":"18","author":"Galindo","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025012220114999300_B31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1210\/endrev\/bnaa017","article-title":"Glycemic monitoring and management in advanced chronic kidney disease","volume":"41","author":"Galindo","year":"2020","journal-title":"Endocr Rev"},{"key":"2025012220114999300_B32","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00125-024-06244-y","article-title":"Diabetes technology in people with diabetes and advanced chronic kidney disease","volume":"67","author":"Galindo","year":"2024","journal-title":"Diabetologia"},{"key":"2025012220114999300_B33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2337\/dc23-1276","article-title":"Assessment of glycemic control by continuous glucose monitoring, hemoglobin A1c, fructosamine, and glycated albumin in patients with end-stage kidney disease and burnt-out diabetes","volume":"47","author":"Kaminski","year":"2024","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2337\/dc21-1579","article-title":"Hypoglycemic and hyperglycemic crises among U.S. adults with diabetes and end-stage kidney disease: population-based study, 2013-2017","volume":"45","author":"Galindo","year":"2022","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B35","unstructured":"Arbor Research Collaborative for Health. DOPPS Practice Monitor\u2013Hemodialysis. Accessed 15 July 2024. Available from https:\/\/www.dopps.org\/DPM-HD\/DPMSlideBrowser.aspx?type=Topic&id=33"},{"key":"2025012220114999300_B36","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ki.2014.419","article-title":"Development and validation of a predictive mortality risk score from a European hemodialysis cohort","volume":"87","author":"Floege","year":"2015","journal-title":"Kidney Int"},{"key":"2025012220114999300_B37","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.2215\/CJN.00640109","article-title":"Key comorbid conditions that are predictive of survival among hemodialysis patients","volume":"4","author":"Miskulin","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025012220114999300_B38","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1111\/bcp.14107","article-title":"Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis","volume":"85","author":"Abdel Shaheed","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2025012220114999300_B39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/08968608221096556","article-title":"The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients","volume":"43","author":"Borkum","year":"2023","journal-title":"Perit Dial Int"},{"key":"2025012220114999300_B40","volume-title":"Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function\u2013Study Design, Data Analysis, and Impact on Dosing.","author":"Food and Drug Administration Center for Drug Evaluation and Research","year":"2020"},{"key":"2025012220114999300_B41","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/clpt.2008.59","article-title":"Emerging evidence of the impact of kidney disease on drug metabolism and transport","volume":"83","author":"Nolin","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2025012220114999300_B42","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","article-title":"Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis","volume":"10","author":"Velenosi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025012220114999300_B43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.ajkd.2023.05.010","article-title":"Use of analog and human insulin in a European hemodialysis cohort with type 2 diabetes: associations with mortality, hospitalization, MACE, and hypoglycemia","volume":"83","author":"Ebert","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.ajkd.2023.10.001","article-title":"Insulin management in patients with diabetes receiving hemodialysis: unanswered questions and way forward","volume":"83","author":"McCoy","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B45","doi-asserted-by":"crossref","first-page":"e1918554","DOI":"10.1001\/jamanetworkopen.2019.18554","article-title":"Comparison of mortality and major cardiovascular events among adults with type 2 diabetes using human vs analogue insulins","volume":"3","author":"Neugebauer","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025012220114999300_B46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1525-1594.2010.01112.x","article-title":"Characterization of insulin adsorption behavior of dialyzer membranes used in hemodialysis","volume":"35","author":"Abe","year":"2011","journal-title":"Artif Organs"},{"key":"2025012220114999300_B47","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2337\/dc09-2176","article-title":"Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis","volume":"33","author":"Sobngwi","year":"2010","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1053\/j.ajkd.2012.11.043","article-title":"Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial","volume":"61","author":"Arjona Ferreira","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/sdi.12198","article-title":"Updates on the management of diabetes in dialysis patients","volume":"27","author":"Rhee","year":"2014","journal-title":"Semin Dial"},{"key":"2025012220114999300_B50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrneph.2013.12","article-title":"Noninsulin glucose-lowering agents for the treatment of patients on dialysis","volume":"9","author":"Flynn","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025012220114999300_B51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1385\/ENDO:28:2:181","article-title":"The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease","volume":"28","author":"Mohideen","year":"2005","journal-title":"Endocrine"},{"key":"2025012220114999300_B52","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.diabres.2008.01.028","article-title":"Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis","volume":"80","author":"Abe","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"2025012220114999300_B53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/dc22-0659","article-title":"Antihyperglycemic medication use among U.S. adults with hemodialysis-dependent kidney disease and comorbid diabetes","volume":"45","author":"Klein","year":"2022","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B54","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1326.2008.00914.x","article-title":"Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency","volume":"10","author":"Chan","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"2025012220114999300_B55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jdi.13126","article-title":"Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: results from a randomized, phase 3 study","volume":"11","author":"Kaku","year":"2020","journal-title":"J Diabetes Investig"},{"key":"2025012220114999300_B56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01382.x","article-title":"Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment","volume":"13","author":"Nowicki","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2025012220114999300_B57","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.diabres.2016.04.034","article-title":"Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: a randomized open-label prospective trial","volume":"116","author":"Abe","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"2025012220114999300_B58","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/1744-9987.12319","article-title":"Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis","volume":"19","author":"Hiramatsu","year":"2015","journal-title":"Ther Apher Dial"},{"key":"2025012220114999300_B59","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jdiacomp.2018.05.018","article-title":"The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis","volume":"32","author":"Yajima","year":"2018","journal-title":"J\u00a0Diabetes Complications"},{"key":"2025012220114999300_B60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000510613","article-title":"The glycemic effect of liraglutide evaluated by continuous glucose monitoring in persons with type 2 diabetes receiving dialysis","volume":"145","author":"Bomholt","year":"2021","journal-title":"Nephron"},{"key":"2025012220114999300_B61","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/dc15-1025","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial","volume":"39","author":"Idorn","year":"2016","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B62","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.numecd.2023.03.023","article-title":"Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: a narrative review","volume":"33","author":"Clemens","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025012220114999300_B63","doi-asserted-by":"crossref","first-page":"1362242","DOI":"10.3389\/fphar.2024.1362242","article-title":"Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis","volume":"15","author":"Otsuka","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025012220114999300_B64","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1046\/j.1523-1755.1999.00389.x","article-title":"Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients","volume":"55","author":"Fleischmann","year":"1999","journal-title":"Kidney Int"},{"key":"2025012220114999300_B65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1053\/j.ajkd.2005.05.020","article-title":"Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population","volume":"46","author":"Kalantar-Zadeh","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B66","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2337\/diacare.25.7.1159","article-title":"Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control","volume":"25","author":"Norris","year":"2002","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B67","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2025012220114999300_B68","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025012220114999300_B69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025012220114999300_B70","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025012220114999300_B71","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025012220114999300_B72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41581-021-00518-z","article-title":"Patient-centred approaches for the management of unpleasant symptoms in kidney disease","volume":"18","author":"Kalantar-Zadeh","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2025012220114999300_B73","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/nep.13243","article-title":"Gastrointestinal symptoms in patients receiving dialysis: a systematic review","volume":"23","author":"Zuvela","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"2025012220114999300_B74","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2215\/CJN.0000000000000232","article-title":"Extending SGLT2 inhibitor use for people undergoing dialysis?","volume":"18","author":"St Peter","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025012220114999300_B75","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41100-024-00523-5","article-title":"SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes","volume":"10","author":"Stepanova","year":"2024","journal-title":"Ren Replace Ther"},{"key":"2025012220114999300_B76","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.2337\/dc23-0554","article-title":"National trends in glucagon prescriptions among U.S. adults with diabetes and end-stage kidney disease treated by dialysis: 2013-2017","volume":"46","author":"Galindo","year":"2023","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B77","doi-asserted-by":"crossref","first-page":"e000763","DOI":"10.1136\/bmjdrc-2019-000763","article-title":"Clinical characteristics and outcomes of patients with end-stage renal disease hospitalized with diabetes ketoacidosis","volume":"8","author":"Galindo","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025012220114999300_B78","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1210\/endrev\/bnac022","article-title":"Consensus recommendations for the use of automated insulin delivery technologies in clinical practice","volume":"44","author":"Phillip","year":"2023","journal-title":"Endocr Rev"},{"key":"2025012220114999300_B79","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41591-021-01453-z","article-title":"Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial","volume":"27","author":"Boughton","year":"2021","journal-title":"Nat Med"},{"key":"2025012220114999300_B80","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00592-022-01880-5","article-title":"One year of hybrid closed loop on peritoneal dialysis: a case report","volume":"59","author":"Rossi","year":"2022","journal-title":"Acta Diabetol"},{"key":"2025012220114999300_B81","doi-asserted-by":"crossref","first-page":"111800","DOI":"10.1016\/j.diabres.2024.111800","article-title":"Case series of using automated insulin delivery to improve glycaemic control in people with type 1 diabetes and end stage kidney disease on haemodialysis","volume":"217","author":"Chaudhry","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2025012220114999300_B82","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1001\/jama.2024.16338","article-title":"Dialysis for chronic kidney failure: a review","volume":"332","author":"Flythe","year":"2024","journal-title":"JAMA"},{"key":"2025012220114999300_B83","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ekir.2023.01.040","article-title":"Narrative review of glycemic management in people with diabetes on peritoneal dialysis","volume":"8","author":"Wijewickrama","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025012220114999300_B84","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2025012220114999300_B85","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/sdi.12929","article-title":"Fragmentation of care as a barrier to optimal ESKD management","volume":"33","author":"Sloan","year":"2020","journal-title":"Semin Dial"},{"key":"2025012220114999300_B86","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/ajkd.2002.34915","article-title":"Diabetes education and care management significantly improve patient outcomes in the dialysis unit","volume":"40","author":"McMurray","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B87","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.34067\/KID.0001802022","article-title":"The integration of diabetic eye screening into hemodialysis units in Northern Ireland","volume":"3","author":"Cushley","year":"2022","journal-title":"Kidney360"},{"key":"2025012220114999300_B88","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.ajkd.2017.10.011","article-title":"Perspectives on research participation and facilitation among dialysis patients, clinic personnel, and medical providers: a focus group study","volume":"72","author":"Flythe","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2025012220114999300_B89","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1681\/ASN.2018101059","article-title":"Cultivating a research-ready dialysis community","volume":"30","author":"Flythe","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"2025012220114999300_B90","article-title":"Trulicity (dulaglutide) injection (package insert)","author":"Eli Lilly and Company","year":"2014"},{"key":"2025012220114999300_B91","article-title":"Victoza (liraglutide) injection (package insert)","author":"Novo Nordisk, Inc.","year":"2010"},{"key":"2025012220114999300_B92","article-title":"Ozempic (semaglutide) injection (package insert)","author":"Novo Nordisk, Inc.","year":"2020"},{"key":"2025012220114999300_B93","article-title":"Mounjaro (tirzepatide) injection (package insert)","author":"Eli Lilly and Company.","year":"2022"},{"key":"2025012220114999300_B94","article-title":"Nesina (alogliptin) tablets (package insert)","author":"Takeda Pharmaceutical Company, Ltd.","year":"2013"},{"key":"2025012220114999300_B95","article-title":"Tradjenta (linagliptin) tablets (package insert)","author":"Boehringer Ingelheim Pharmaceuticals, Inc.","year":"2011"},{"key":"2025012220114999300_B96","article-title":"Onglyza (saxagliptin) tablets (package insert)","author":"Bristol-Myers Squibb Company.","year":"2009"},{"key":"2025012220114999300_B97","article-title":"Januvia (sitagliptin) tablets (package insert)","author":"Merck Sharp & Dohme Corporation.","year":"2006"},{"key":"2025012220114999300_B98","article-title":"Amaryl (glimepiride) tablets (package insert)","author":"Sanofi-Aventis U.S., LLC.","year":"1999"},{"key":"2025012220114999300_B99","article-title":"Glucotrol (glipizide) tablets (package insert)","year":"1994"},{"key":"2025012220114999300_B100","article-title":"Actos (pioglitazone hydrochloride) tablets (package insert)","author":"Takeda Pharmaceuticals America, Inc.","year":"1999"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/2\/164\/792955\/dci240081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/2\/164\/792955\/dci240081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T15:13:14Z","timestamp":1737558794000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/2\/164\/157635\/Glycemic-Management-and-Individualized-Diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,18]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dci24-0081","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}